Genus Oncology was formed in 2007 with a mission of discovering, developing, and commercializing new anti-cancer agents that target the Mucin 1 (MUC1) oncoprotein. The incidence of overexpressed MUC1 in a wide array of carcinomas and hematologic malignancies has been known by researchers for many years. Until now, no viable approach existed to selectively target and block the function of MUC1 that leads to the formation of tumors.


Research Grants 1 show all


Patents 51show all

  • 25
    A61K - Preparations for medical, dental, or toilet purposes
  • 21
    C07K - Peptides
  • 5
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 3
    C07D - Heterocyclic compounds

Clinical Trials 2show all

2Phase 1

Contact Information

3 Hawthorn Parkway Suite 250
Vernon Hills, IL 60061
United States


Total FundingEmployeesLast Funding DateStatus

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2011-05-01Series ALightbank